Bayforest Capital Ltd Decreases Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Bayforest Capital Ltd reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 90.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,644 shares of the biotechnology company’s stock after selling 53,759 shares during the period. Bayforest Capital Ltd’s holdings in Arrowhead Pharmaceuticals were worth $195,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Arrowhead Pharmaceuticals by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after buying an additional 28,193 shares during the last quarter. Marshall Wace LLP boosted its stake in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. Norges Bank purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth about $30,414,000. Goldman Sachs Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after purchasing an additional 447,456 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Arrowhead Pharmaceuticals by 5.4% during the second quarter. Bank of New York Mellon Corp now owns 818,079 shares of the biotechnology company’s stock worth $12,926,000 after purchasing an additional 42,040 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Activity

In other news, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the sale, the chief operating officer owned 474,908 shares of the company’s stock, valued at $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Perry sold 16,250 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the transaction, the director owned 115,240 shares in the company, valued at approximately $7,033,097.20. This trade represents a 12.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 510,836 shares of company stock valued at $33,603,060. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ARWR shares. Morgan Stanley raised their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. The Goldman Sachs Group upped their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Finally, Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $73.00.

Arrowhead Pharmaceuticals Trading Down 0.6%

NASDAQ:ARWR opened at $65.54 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock’s 50 day simple moving average is $58.31 and its 200-day simple moving average is $37.48. The firm has a market cap of $8.91 billion, a P/E ratio of -819.15 and a beta of 1.21.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.